Announcements Trials

Browse Landscape

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 10 Expanded_access 1

Sponsor

Cancer Type

Conditions

Interventions

tazemetostat 2 Trabectedin 2 selinexor 1 olaratumab 1 balstilimab 1 anlotinib 1 TH 302 1 Proton Pump Inhibitors 1 Hydrocortisone 1 DOXO-EMCH 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Sarcoma × olaratumab × Clear all

NCT03994627 2024-12-16

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Eli Lilly and Company

Approved for marketing

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡